|
Schering-Plough allergy drug deal has significant potential (Pharmaceutical Business Review)
2007-01-11 09:01:12
The agreement between ALK-Abello and Schering-Plough on immunotherapy compounds welcomes the first tablet-based vaccine against grass pollen allergy on the global market. While immunotherapy is increasingly popular in Europe, the US remains a novice, offering great potential for ALK-Abellos Grazax. Lisette Oversteegen, respiratory analyst at Datamonitor, investigatesâŚ
=== Putting the NEWS back into NEWSgroups, It's Just One of Today's Top 10 Anticholinergics News Reports: http://www.ng2000.com/fw.php?tp=anticholinergics |
Dieta forum Ślub biuro nieruchomości Teksty piosenek folia do oczek wodnych |
